Table 2.
Estimated survival probability at a specific time (months) by propensity score method.a
| IV edaravone-treated cases | Non-IV edaravone-treated controls | |
|---|---|---|
| 12 months | 0.837 (0.797–0.880) | 0.704 (0.654–0.759) |
| 18 months | 0.685 (0.632–0ּ.743) | 0.587 (0.532–0.648) |
| 24 months | 0.591 (0.533–0.655) | 0.490 (0.434–0.554) |
| 30 months | 0.499 (0.438–0.569) | 0.426 (0.370–0.491) |
a
The estimated probability of survival at the different time points is not used to determine significance in overall survival; therefore, any significant differences in survival probability are derived from differences in overall survival. (HR, 0.73; 95% CI, 0.59–0.91; p=0.005).
IV, intravenous.